Ray, Jessica <br/><br/>
miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.  [electronic resource] 

 -  Cancer letters  03 2020 
 - 107-117 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2019.12.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alitretinoin--administration & dosage<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--metabolism<br/>Cell Line, Tumor<br/>Chemoradiotherapy, Adjuvant--methods<br/>Disease-Free Survival<br/>Down-Regulation<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Gene Knockdown Techniques<br/>Humans<br/>Kallikreins--blood<br/>Kaplan-Meier Estimate<br/>Male<br/>Mice<br/>MicroRNAs--agonists<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Recurrence, Local--blood<br/>Primary Cell Culture<br/>Prognosis<br/>Prostate--pathology<br/>Prostate-Specific Antigen--blood<br/>Prostatectomy<br/>Prostatic Neoplasms--blood<br/>Radiation Tolerance--drug effects<br/>Retinoid X Receptor alpha--agonists<br/>Survival Rate<br/>Time Factors<br/>Xenograft Model Antitumor Assays